Peptide Therapeutics Market Research Report by Technology, API Type, Drug Class, Application - Global Forecast to 2026 - Cumulative Impact of COVID-19 -

·5 min read

DUBLIN, May 23, 2022--(BUSINESS WIRE)--The "Peptide Therapeutics Market Research Report by Technology (Hybrid Phase, Liquid Phase, and Solid Phase), API Type, Drug Class, Application, End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to's offering.

The Global Peptide Therapeutics Market size was estimated at USD 24,461.45 million in 2020, USD 27,134.60 million in 2021, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.97% to reach USD 45,681.04 million by 2026.

In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Cumulative Impact of COVID-19:

The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects.

It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others.

Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

  • AmbioPharm Inc.

  • Amgen Inc.

  • AstraZeneca PLC

  • Bachem Holding AG

  • Bristol-Myers Squibb Company

  • CordenPharma International

  • Eli Lilly and Company

  • F. Hoffmann-La Roche AG

  • GlaxoSmithKline PLC

  • Hemmo Pharmaceuticals Pvt Ltd.

  • Ipsen S.A.

  • Merck & Co., Inc.

  • Novartis International AG

  • Novo Nordisk A/S

  • Pfizer Inc.

  • PolyPeptide Group

  • Sanofi S.A.

  • Takeda Pharmaceutical Company Limited

  • Teva Pharmaceutical Industries Ltd.

  • Zealand Pharma A/S

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics

5.1.1. Drivers Increasing prevalence of cancer, cardiovascular disorders (CVDs) and metabolic disorder Technology advancement and R & D investment in new peptides

5.1.2. Restraints Poor chemical and physical stability and a short circulating plasma half-life of naturally occurring peptides

5.1.3. Opportunities Presence of strong product pipeline portfolio Adoption of new platforms that develop next-generation protein or peptide therapeutics

5.1.4. Challenges Presence of stringent safety regulations

5.2. Cumulative Impact of COVID-19

6. Peptide Therapeutics Market, by Technology

6.1. Introduction

6.2. Hybrid Phase

6.3. Liquid Phase

6.4. Solid Phase

7. Peptide Therapeutics Market, by API Type

7.1. Introduction

7.2. CMO

7.3. In-house

8. Peptide Therapeutics Market, by Drug Class

8.1. Introduction

8.2. Calcitonins

8.3. Glucagon & Analogs

8.4. Insulins

8.5. Luteinizing Hormone-Releasing Hormone

8.6. Somatostatins

8.7. Vasopressin

9. Peptide Therapeutics Market, by Application

9.1. Introduction

9.2. Anti-infective

9.3. Cancer

9.4. Cardio Vascular Disease Respiratory

9.5. Central Nervous System

9.6. Dermatology

9.7. Gastrointestinal

9.8. Metabolic

9.9. Renal

10. Peptide Therapeutics Market, by End User

10.1. Introduction

10.2. Hospitals

10.3. Pharmaceutical Industries

10.4. Research Laboratories

11. Americas Peptide Therapeutics Market

11.1. Introduction

11.2. Argentina

11.3. Brazil

11.4. Canada

11.5. Mexico

11.6. United States

12. Asia-Pacific Peptide Therapeutics Market

12.1. Introduction

12.2. Australia

12.3. China

12.4. India

12.5. Indonesia

12.6. Japan

12.7. Malaysia

12.8. Philippines

12.9. Singapore

12.10. South Korea

12.11. Taiwan

12.12. Thailand

13. Europe, Middle East & Africa Peptide Therapeutics Market

13.1. Introduction

13.2. France

13.3. Germany

13.4. Italy

13.5. Netherlands

13.6. Qatar

13.7. Russia

13.8. Saudi Arabia

13.9. South Africa

13.10. Spain

13.11. United Arab Emirates

13.12. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix

14.1.1. Quadrants

14.1.2. Business Strategy

14.1.3. Product Satisfaction

14.2. Market Ranking Analysis

14.3. Market Share Analysis, By Key Player

14.4. Competitive Scenario

14.4.1. Merger & Acquisition

14.4.2. Agreement, Collaboration, & Partnership

14.4.3. New Product Launch & Enhancement

14.4.4. Investment & Funding

14.4.5. Award, Recognition, & Expansion

15. Company Usability Profiles

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900